 |
| MMWR Early Release Vol. 65, Early Release May 10, 2016 |
| In this report |
| Interim Guidance for Zika Virus Testing of Urine — United States, 2016 MMWR Morb Mortal Wkly Rep 2016;65(Early Release) Recent reports suggest Zika virus RNA can be detected in urine for at least 2 weeks after onset of symptoms. Currently, the CDC Trioplex rRT-PCR assay is the only diagnostic tool authorized by the Food and Drug Administration for Zika virus testing of urine. On the basis of the newly available data, CDC recommends Zika virus rRT-PCR be performed on urine collected <14 days after onset of symptoms in patients with suspected Zika virus disease. |
| Comparison of Test Results for Zika Virus RNA in Urine, Serum, and Saliva Specimens from Persons with Travel-Associated Zika Virus Disease — Florida, 2016 Andrea M. Bingham, PhD; Marshall Cone, MPH; Valerie Mock; et al. MMWR Morb Mortal Wkly Rep 2016;65(Early Release) As of April 20, 2016, the Florida Department of Health Bureau of Public Health Laboratories (BPHL) tested specimens from 913 persons who met state criteria for Zika virus testing. On the basis of previous small case studies reporting real time reverse-transcription polymerase chain reaction detection of Zika virus RNA in urine, saliva, and semen, the BPHL collected multiple specimen types from persons with suspected Zika virus disease. BPHL testing results suggest urine might be the preferred specimen type to identify acute Zika virus disease. |
| Reduced Incidence of Chikungunya Virus Infection in Communities with Ongoing Aedes Aegypti Mosquito Trap Intervention Studies — Salinas and Guayama, Puerto Rico, November 2015–February 2016 Olga D. Lorenzi, MS; Chelsea Major, MPH; Veronica Acevedo, MS; et al. MMWR Morb Mortal Wkly Rep 2016;65(Early Release) Conventional vector control approaches often fail to result in effective and sustainable prevention of infection with viruses transmitted by Aedes mosquitoes. CDC developed an Autocidal Gravid Ovitrap (AGO) to attract and capture the female Aedes aegypti mosquitoes responsible for transmission of infectious agents to humans. Since 2012, four communities in two municipalities in southern Puerto Rico, Salinas and Guayama, have participated in an ongoing field trial of AGO traps to control Ae. aegypti mosquitoes. According to preliminary findings, lower incidence of chikungunya virus infection in the intervention compared with nonintervention communities occurred in the context of tenfold lower mosquito densities in the intervention areas with AGO traps. |
| MMWR Masthead |
| Department of Health and Human Services Centers for Disease Control and Prevention |
|
The CDC has reached over 1 million email subscribers. Thank you for your support. Modify/Update Subscriber Preferences or Unsubscribe | Learn about CDC Updates Questions or problems? Please contact support@xxxxxxxxxxxxxxx. |
   |
   |
| This email was sent to list-cdc@xxxxxxxxxxx using GovDelivery,on behalf of: Centers for Disease Control and Prevention • 1600 Clifton Rd • Atlanta, GA 30333 • 1-800-CDC-INFO (800-232-4636) |  |
